Procaps Group Sa Stock Today

PROC Stock  USD 1.63  0.12  7.95%   

Performance

4 of 100

 
Weak
 
Strong
Insignificant

Odds Of Distress

Less than 45

 
High
 
Low
Below Average
Procaps Group is trading at 1.63 as of the 3rd of December 2024, a 7.95% up since the beginning of the trading day. The stock's open price was 1.51. Procaps Group has 45 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. Equity ratings for Procaps Group SA are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 6th of June 2024 and ending today, the 3rd of December 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
30th of September 2021
Category
Healthcare
Classification
Health Care
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company was founded in 1977 and is based in Luxembourg, Luxembourg. Procaps Group is traded on NASDAQ Exchange in the United States. The company has 112.82 M outstanding shares of which 113.8 K shares are at this time shorted by private and institutional investors with about 1.65 trading days to cover. More on Procaps Group SA

Moving together with Procaps Stock

  0.73A Agilent TechnologiesPairCorr
  0.73ME 23Andme HoldingPairCorr

Moving against Procaps Stock

  0.74VCEL Vericel Corp OrdPairCorr
  0.56VANI Vivani MedicalPairCorr
  0.56VCYT VeracytePairCorr
  0.56SABSW SAB BiotherapeuticsPairCorr
  0.53VERA Vera TherapeuticsPairCorr
  0.52DSGN Design TherapeuticsPairCorr

Procaps Stock Highlights

Founder ChairmanRuben Minski
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover1.011.02
Slightly Down
Very volatile
Gross Profit Margin0.460.53
Fairly Down
Slightly volatile
Net Debt258.6 M218.6 M
Fairly Up
Slightly volatile
Total Current Liabilities287.2 M423.6 M
Way Down
Slightly volatile
Non Current Liabilities Total80.1 M84.3 M
Notably Down
Slightly volatile
Total Assets445.4 M529.2 M
Fairly Down
Slightly volatile
Total Current Assets262 M342.1 M
Way Down
Slightly volatile
Total Cash From Operating Activities40.6 M63 M
Way Down
Slightly volatile
Debt Levels
Procaps Group can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Procaps Group's financial leverage. It provides some insight into what part of Procaps Group's total assets is financed by creditors.
Liquidity
Procaps Group SA currently holds 285.94 M in liabilities with Debt to Equity (D/E) ratio of 6.02, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Procaps Group SA has a current ratio of 1.51, which is within standard range for the sector. Note, when we think about Procaps Group's use of debt, we should always consider it together with its cash and equity.

Change To Inventory

(4.81 Million)
Procaps Group SA (PROC) is traded on NASDAQ Exchange in USA. It is located in 9 Rue de Bitbourg, Luxembourg, Luxembourg, 1273 and employs 5,500 people. Procaps Group is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 183.34 M. Procaps Group SA conducts business under Biotechnology sector and is part of Health Care industry. The entity has 112.82 M outstanding shares of which 113.8 K shares are at this time shorted by private and institutional investors with about 1.65 trading days to cover. Procaps Group SA currently holds about 37.55 M in cash with 62.99 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.37.
Check Procaps Group Probability Of Bankruptcy
Ownership Allocation
Procaps Group owns a total of 112.82 Million outstanding shares. Procaps Group holds majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 83.02 pct. of Procaps Group SA outstanding shares that are owned by insiders implies they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Procaps Ownership Details

Procaps Stock Institutional Holders

InstituionRecorded OnShares
Geode Capital Management, Llc2024-09-30
28.9 K
Activest Wealth Management2024-09-30
10 K
Pineridge Advisors Llc2024-09-30
250
Morgan Stanley - Brokerage Accounts2024-09-30
100.0
State Street Corp2024-09-30
0.0
Renaissance Technologies Corp2024-06-30
0.0
Exome Asset Management Llc2024-09-30
0.0
Royal Bank Of Canada2024-09-30
0.0
Ubs Group Ag2024-06-30
0.0
View Procaps Group Diagnostics

Procaps Group Historical Income Statement

At present, Procaps Group's Total Revenue is projected to increase significantly based on the last few years of reporting. The current year's Gross Profit is expected to grow to about 236.9 M, whereas Tax Provision is forecasted to decline to about 12.7 M. View More Fundamentals

Procaps Stock Against Markets

When determining whether Procaps Group SA is a strong investment it is important to analyze Procaps Group's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Procaps Group's future performance. For an informed investment choice regarding Procaps Stock, refer to the following important reports:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Procaps Group SA. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Procaps Group. If investors know Procaps will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Procaps Group listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.64)
Earnings Share
0.51
Revenue Per Share
4.097
Quarterly Revenue Growth
0.073
Return On Assets
0.0628
The market value of Procaps Group SA is measured differently than its book value, which is the value of Procaps that is recorded on the company's balance sheet. Investors also form their own opinion of Procaps Group's value that differs from its market value or its book value, called intrinsic value, which is Procaps Group's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Procaps Group's market value can be influenced by many factors that don't directly affect Procaps Group's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Procaps Group's value and its price as these two are different measures arrived at by different means. Investors typically determine if Procaps Group is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Procaps Group's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.